Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sniffing out COVID: new At-Home smell test could spot infections early

NCT ID NCT05040659

Diagnosis Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a simple, at-home smell test to see if it can detect COVID-19 infection and track how smell recovers over time. About 1000 adults, including those with known smell loss and healthy volunteers, will use smell cards to rate odor intensity, identification, and discrimination. The goal is to see if this test is a reliable tool for screening and monitoring smell changes related to COVID-19.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AROMHA Longitudinal Smell Test (a set of smell cards)
What this could lead to
If successful, this could provide a simple, at-home way to detect COVID-19 and monitor smell recovery, helping guide treatment and reduce spread.
What could go wrong
This is an early-stage study focused on measurement, not treatment. The test may not be accurate enough for widespread use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

1. Diagnosis of Anosmia 2. Healthy controls 3. Asymptomatic patients 4. Participants with COVID-19-related smell loss 5. PASC with persistent smell loss

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For anosmic patients/healthy controls: Inclusion criteria 1. Known anosmia (for anosmic patients only) 2. Age greater than or equal to 18 3. Access to phone, tablet or computer connected to the internet. Exclusion criteria 1\. Known odor-evoked adverse effects, e.g. asthma. For asymptomatic participants: Inclusion criteria 1. No symptoms of COVID infection at the time of enrollment. 2. Age greater than or equal to 18 3. Access to phone, tablet or computer connected to the internet. Exclusion criteria 1\. Known odor-evoked adverse effects, e.g. asthma. For participants with COVID-19-related smell loss: Inclusion criteria 1. Past infection of SARS-CoV-2 virus as validated by a previous PCR or antigen test 2. Age greater than or equal to 18 3. Access to phone, tablet or computer connected to the internet. Exclusion criteria 1\. Known odor-evoked adverse effects, e.g. asthma.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anosmia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anosmia COVID-19 influenza long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anosmia Asymptomatic COVID-19 COVID-19 respiratory infection Healthy Influenza Pasc post acute sequelae of COVID-19

Contacts and locations

Locations

  • Massachusetts General Hospital

    Boston, Massachusetts, 02129, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.